Abstract 809P
Background
Gynecological cancer may have severe implications in women, as these diagnoses are likely to have negative consequences on mental health and socioeconomic status. We used the Swedish national population and healthcare registries to assess the association between diagnosis of endometrial or cervical cancer and risk for mental disorders, as well as for socioeconomic consequences.
Methods
We performed a population-based nested case-control study based on more than 5 million women in Sweden, identifying 6,060 cases of cervical cancer and 17,932 cases of endometrial cancer diagnosed during 2006-2018. Each cancer case was matched with five healthy controls randomly selected from the population born in the same year. Data on comprehensive set of mental disorders, loss of employment, early retirement or need for sickness benefit, family receipt of financial assistance, decrease of individual income and family income before versus after cancer diagnosis were retrieved from population registries. Conditional logistic regression and stratified Cox regression models with confounder adjustment were conducted to estimate odds ratios (OR) and 95% confidence intervals (CI).
Results
Mental disorders were prevalent to a moderate degree before diagnosis among cervical cancer patients, but less prevalent in endometrial cancer patients. After cancer diagnosis, incident (i.e. new) mental disorders started emerging within the first 2-5 years and then persisted. The risk was higher following cervical cancer (OR=3.7, 95% CI=3.5-4.1) as compared to endometrial cancer (OR=2.1, 95% CI=2.0-2.2). Before cancer diagnosis, economic status was comparable between cancer patients and control women. Financial assistance and income decrease rose early after diagnosis, with 1.2-2.1 times increased risk among cancer patients. Unemployment, early retirement and need for sickness benefit doubled from two years after cancer diagnosis and onwards. Impact was more pronounced among cervical cancer patients.
Conclusions
Women with cervical cancer and endometrial cancer are affected mentally and financially after the cancer diagnosis. The impact is more pronounced among cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD Sweden.
Disclosure
J. Wang, K. Sundström: Financial Interests, Institutional, Research Funding: MSD. A.L. Feldman: Financial Interests, Institutional, Other: Has been part of research collaborations within partnership programs between Karolinska Institutet and respectively MSD Sweden/Merck and Janssen Pharmaceutica NV. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11